ProCE Banner Activity

GMALL-INITIAL1: Inotuzumab Ozogamicin Induction Therapy Followed by Standard Chemotherapy in Older Patients With B-Lymphoblastic Leukemia

Slideset Download
Conference Coverage

Adding inotuzumab ozogamicin to induction therapy resulted in a high response rate and promising 2-year survival in older patients with newly diagnosed CD22+ B-lymphoblastic leukemia.

Released: December 19, 2022

Expiration: December 18, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen